Experimental and Molecular Pathology (Dec 2023)

SARS-CoV-2 hampers dopamine production in iPSC-derived dopaminergic neurons

  • G. Cappelletti,
  • E.V. Carsana,
  • G. Lunghi,
  • S. Breviario,
  • C. Vanetti,
  • A.B. Di Fonzo,
  • E. Frattini,
  • M. Magni,
  • S. Zecchini,
  • M. Clerici,
  • M. Aureli,
  • C. Fenizia

Journal volume & issue
Vol. 134
p. 104874

Abstract

Read online

An increasing number of patients experiences prolonged symptoms, whose profile and timeline remain uncertain, a condition that has been defined as post COVID. The majority of recovered hospitalized patients manifests at least one persistent symptom even sixty days after the first clinical manifestation's onset. Particularly, in light of the COVID-19-related symptomatology, it has been hypothesized that SARS-CoV-2 might affect the dopamine pathway. However, no scientific evidence has been produced so far.To this end, human iPSC-derived dopaminergic neurons were infected with EU, Delta and Omicron SARS-CoV-2 variants. The infection with EU and Delta variants, but not with Omicron, results in a reduced intracellular content and extracellular release of dopamine. Indeed, the tyrosine hydroxylase was found to be significantly upregulated at the mRNA level, while being greatly reduced at the protein level. The major downstream synthetic enzyme DOPA-decarboxylase and the dopamine transporter were significantly downregulated both at the mRNA and protein level. Notably, in vitro SARS-CoV-2 infection was also associated with an altered MAP2 and TAU expression and with an increased presence of neuronal stress markers.These preliminary observations suggest that the dopamine metabolism and production are affected by SARS-CoV-2, partially explaining some of the neurological symptoms manifested.

Keywords